Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis.
Arteriovenous (AV) graft use as hemodialysis access remains highly prevalent, with a consequent high thrombosis rate. The magnitude of this problem requires that all potentially modifiable risk factors for graft thrombosis be thoroughly investigated. During graft surgery, topical bovine thrombin is often administered, which can lead to the development of antibovine thrombin antibodies and subsequent hemostatic changes. A recent study correlated the presence of plasma antibovine thrombin antibodies with graft thrombosis in hemodialysis patients. We therefore hypothesized that perioperative topical bovine thrombin exposure would lead to the development of antibovine thrombin antibodies and graft thrombosis. We screened 314 hemodialysis patients and identified 73 patients who had 74 grafts placed for whom complete data on perioperative topical bovine thrombin exposure and subsequent graft outcomes was available. Sixty-one of these patients were available for retrospective measurement of antibovine thrombin antibodies, antihuman thrombin antibodies, and the thrombin activation markers thrombin activatible fibrinolysis inhibitor (TAFI) and thrombin precursor protein (TpP). In these grafts, there was no significant association between topical bovine thrombin exposure and primary assisted patency (P = 0.37). The presence of antibovine thrombin antibodies (P = 0.13), antihuman thrombin antibodies (P = 0.10), and increased TAFI (P = 0.18) were associated with trends toward reduced primary assisted patency which did not reach significance. There was a correlation between antibovine thrombin antibodies and antihuman thrombin antibodies (r = 0.30, P < 0.0001) and between TAFI and TpP trade mark (r = 0.30, P < 0.0001), but no significant correlation between topical bovine thrombin exposure and elevated levels of antibovine thrombin antibodies, antihuman thrombin antibodies, TAFI or TpP trade mark. We conclude that perioperative topical bovine thrombin exposure is not associated with subsequent graft thrombosis.
Vannorsdall
Mark D
MD
Division of Nephrology, Maine Medical Center, Portland, Maine 04102, USA.
Arkel
Yale S
YS
Ku
De-Hui
DH
Lucas
F Lee
FL
Himmelfarb
Jonathan
J
D000368:Aged; D000818:Animals; D000906:Antibodies / Q000097:blood; D002417:Cattle; D005260:Female; D006083:Graft Occlusion, Vascular / Q000209:etiology* / Q000517:prevention & control; D006490:Hemostatics / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis; D012189:Retrospective Studies; D013917:Thrombin / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D014654:Vascular Patency
D000906:Antibodies; D006490:Hemostatics; D013917:Thrombin